summary of the phase 3 data for amifampridine phosphate to treat lems
Published 9 years ago • 882 plays • Length 4:49Download video MP4
Download video MP3
Similar videos
-
3:20
lems is not myasthenia gravis
-
1:57
phase iii ahead 3-45 trial of lecanemab for preclinical alzheimer’s disease
-
59:44
uofl dept. of medicine grand rounds: dr. myles wolf
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
11:26
alnylam’s phase 3 clinical trials with givosiran
-
1:35
flt3 inhibitor maintenance after allo-sct for aml
-
4:29
top-line results announced from phase 3 trial of momelotinib for myelofibrosis
-
3:10
tresr trial: novel atr inhibitor, rp-3500, for advanced solid tumors
-
1:33
outcomes of reduced intensity allosct in patients with accelerated-phase myelofibrosis
-
2:13
multiple sulfatase deficiency explained
-
1:49
the prognostic value of flt3-itd residual disease in aml
-
1:19
next steps for research into the nlrp3 inflammasome in dementia
-
2:34
sf3b1-mutant mds: a new disease subtype
-
1:28
flt3 inhibitors for treating aml
-
1:06:59
dr. michael mcgrath on modulating systemic immunity as treatment for als
-
2:19
novel potent and selective flt3 inhibitors
-
2:40
an overview of the safety profile of flt3 inhibitors in aml
-
2:23
fda requires additional trials for catalyst pharmaceuticals’ rare disease drug
-
5:03
is there data to support routine use of flt3 inhibitors in aml patients outside of a clinical trial?